Hewitt H B, Blake E R, Walder A S
Br J Cancer. 1976 Mar;33(3):241-59. doi: 10.1038/bjc.1976.37.
Extensive experience with isotransplants of 27 different tumours (leukaemias, sarcomata, carcinomata), all of strictly spontaneous origin in laboratory bred mice of low cancer strains CBA/Ht and WHT/Ht, has revealed no evidence of tumour immunogenicity. Of approximately 20,000 maintenance transplants, none failed and none regressed; of almost 10,000 carefully observed tumours arising from small or minimal inocula of tumour cells, none spontaneously regressed. The number of injected viable tumour cells required to give a 50% probability of successful transplantation (the TD50) ranged from approximately 1 cell to greater than 10,000 cells among the 27 tumours; high TD50 values, which were dramatically reduced by various procedures having no immunological significance, did not signify active "resistance" of the hosts. In the case of all of 7 randomly selected tumours, prior "immunization" of recipients with homologous lethally irradiated cells increased their tumour receptivity. Several experiments using various tumours failed to give evidence that immunity could be non-specifically induced or that a massive preponderance of lymphocytes from specifically sensitized mice could inhibit tumour transplantation or growth in vivo; no trace of "resistance" to tumour was adopted by isogeneic recipients of lymphocytes from regional nodes of tumour bearers. A limited review of the recent literature on tumour immunity shows that practically all the animal data presented in support of a general theory of tumour immunogenicity or to provide a basis for active clinical immunotherapy have been obtained from transplanted tumour systems which entail artefactual immunity associated with viral or chemical induction of the tumours or their allogeneic transplantation. It is suggested that isotransplants of spontaneously arising tumours are the only appropriate models of human cancer and that any genuine rapport between the animal laboratory and the clinic requires their exclusive use.
对27种不同肿瘤(白血病、肉瘤、癌)的同基因移植进行了广泛研究,所有这些肿瘤均严格源自低癌株CBA/Ht和WHT/Ht实验室饲养小鼠的自发肿瘤,结果未发现肿瘤免疫原性的证据。在大约20,000次维持移植中,无一失败,无一消退;在近10,000个由少量或微量肿瘤细胞接种产生的经过仔细观察的肿瘤中,无一自发消退。在这27种肿瘤中,使移植成功概率达到50%所需注射的活肿瘤细胞数量从约1个细胞到超过10,000个细胞不等;高TD50值在经过各种无免疫学意义的处理后显著降低,但这并不意味着宿主具有主动“抗性”。在随机选择的7种肿瘤中,所有情况下,用同源致死剂量照射的细胞对受体进行预先“免疫”都会增加它们对肿瘤的接受性。使用多种肿瘤进行的几项实验未能证明免疫可以被非特异性诱导,也未能证明来自特异性致敏小鼠的大量淋巴细胞优势能够抑制体内肿瘤移植或生长;肿瘤携带者区域淋巴结淋巴细胞的同基因受体未表现出对肿瘤的“抗性”迹象。对近期肿瘤免疫文献的有限综述表明,实际上所有支持肿瘤免疫原性一般理论或为主动临床免疫治疗提供基础的动物数据均来自移植肿瘤系统,这些系统存在与病毒或化学诱导肿瘤或其同种异体移植相关的人为免疫。有人认为,自发产生肿瘤的同基因移植是人类癌症的唯一合适模型,动物实验室与临床之间的任何真正联系都需要专门使用这些模型。